Aug. 9 at 1:02 AM
$GANX Khalid and Gene are very wisely beginning to position Gain as a platform company, versus a single drug company, with a vast multi target franchise opportunity in neurodegeneration. With Magellan capable of generating an endless organic pipeline of additional molecules which may be advanced to the clinic, all building upon what they have learned from GT-00287.
While we will never get there unfortunately, this is similar to how
$BIIB (Biogen) was started way back when and trading at just a couple dollars a share, along with
$JAZZ. Ironically, Gene was one of the first analysts to initiate and recommend both names in their infancy, early on on his career as an analyst.
